Moderna’s stock has rallied on hantavirus research that is ‘early-stage’ in nature

Moderna’s stock has rallied on hantavirus research that is ‘early-stage’ in nature

The biotech company a pre-clinical program with the U.S. Army and a vaccine center at a Korean university.

Original Source

Read the full article at Marketwatch →

KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.